Genmab A/S announced the initiation of a share buy-back program, aiming to repurchase up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion. The program is designed to reduce capital and fulfill commitments under the company's Restricted Stock Unit program.
The share buy-back program commenced on March 26, 2025, and is expected to conclude no later than July 10, 2025. Genmab has entered into a non-discretionary instruction with Goldman Sachs International to execute the program, ensuring independent trading decisions.
As of March 25, 2025, Genmab held 2,537,988 treasury shares, representing 3.83% of its share capital. The program will be conducted on Nasdaq Copenhagen and Multilateral Trading Facilities, adhering to regulatory price and volume conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.